Early research (Phase 1)Ended earlyNCT04762602What this trial is testingHMPL-306 in Advanced Solid Tumors With IDH MutationsWho this might be right forIsocitrate Dehydrogenase Gene Mutation Hutchmed 42
Very early researchLooking for participantsNCT05851378What this trial is testingHyperpolarized Carbon-13 Alpha-ketoglutarate Imaging in IDH Mutant GliomaWho this might be right forAdult Gliomas, Mixed Robert Bok, MD, PhD 40
Testing effectiveness (Phase 2)WithdrawnNCT02977689What this trial is testingTrial of IDH305 in IDH1 Mutant Grade II or III GliomaWho this might be right forGlioma NYU Langone Health
Testing effectiveness (Phase 2)Study completedNCT01915498What this trial is testingPhase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) MutationWho this might be right forHematologic Neoplasms Celgene 345
Testing effectiveness (Phase 2)Looking for participantsNCT06717958What this trial is testingProspective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Neoplasia With IDH1 (Isocitrate Dehydrogenase 1) MutationWho this might be right forAMLMDS Technische Universität Dresden 76
Testing effectiveness (Phase 2)Active Not RecruitingNCT03953898What this trial is testingUsing the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) MutationWho this might be right forAcute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAcute Myeloid Leukemia Post Cytotoxic Therapy+4 more National Cancer Institute (NCI) 14
Early research (Phase 1)Active Not RecruitingNCT03749187What this trial is testingBGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV GliomasWho this might be right forGlioblastomaIDH1 Gene MutationIDH2 Gene Mutation+7 more University of California, San Francisco 78
Testing effectiveness (Phase 2)Active Not RecruitingNCT02677922What this trial is testingAssess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction ChemotherapyWho this might be right forLeukemia, Myeloid, Acute Celgene 130
Early research (Phase 1)Study completedNCT02071862What this trial is testingStudy of the Glutaminase Inhibitor CB-839 in Solid TumorsWho this might be right forSolid TumorsTriple-Negative Breast CancerNon Small Cell Lung Cancer+7 more Calithera Biosciences, Inc 210
Testing effectiveness (Phase 2)Study completedNCT02496741What this trial is testingMetformin And Chloroquine in IDH1/2-mutated Solid TumorsWho this might be right forGliomaCholangiocarcinomaChondrosarcoma Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) 15
Testing effectiveness (Phase 2)Looking for participantsNCT05588141What this trial is testingA Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) MutationsWho this might be right forBrain TumorCancer National Cancer Institute (NCI) 96
Early research (Phase 1)Ended earlyNCT04764474What this trial is testingHMPL-306 in Advanced Hematological Malignancies With mIDHWho this might be right forIsocitrate Dehydrogenase Gene Mutation Hutchmed 46
Large-scale testing (Phase 3)Study completedNCT02577406What this trial is testingAn Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 MutationWho this might be right forLeukemia, MyeloidIsocitrate Dehydrogenase Celgene 319
Large-scale testing (Phase 3)Not Yet RecruitingNCT05987358What this trial is testingA Clinical Study of TQB3454 Tablets in the Treatment of Advanced Biliary Carcinoma.Who this might be right forBiliary Carcinoma Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 165